Madrid, a two-time survivor of Stage 4 cancer, weaves together his life experiences – including his Italian heritage, the power of family connection, and effective mindset techniques – into an ...

A sweeping analysis of over 50 million people found that a cluster of common health conditions significantly raises the risk ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

On this Valentine's Day, a couple recalls everything they had to overcome from long distance to three cancer diagnoses over ...

A spokesperson for the charity said as symptoms can be vague, pancreatic cancer is difficult to diagnose at an early stage.

Even before a tumor in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment ...

Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a ...

Diabetes was associated with an increased risk of pancreatic cystic neoplasms (PCNs), with longer disease duration linked to progressively higher risk, according to a nationwide population-based ...

Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

NovoCure (NVCR) stock rose 29% Thursday on early FDA approval for Optune Pax pancreatic cancer device, prompting H.C. Wainwright to raise target to $47.

NovoCure shares are popping Thursday following a major FDA approval that sent the stock soaring nearly 30% in Wednesday's ...